0QNA.L - Basilea Pharmaceutica AG

LSE - LSE Prezzo differito. Valuta in CHF.
45,75
+0,51 (+1,13%)
Alla chiusura: 05:47PM BST
Il grafico dei titoli non è supportato dal tuo browser attuale
Chiusura precedente45,24
Aperto45,45
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno45,45 - 46,10
Intervallo di 52 settimane30,05 - 55,30
Volume3.816
Media Volume5.902
Capitalizzazione4,936M
Beta (5 anni mensile)0,82
Rapporto PE (ttm)N/D
EPS (ttm)-0,58
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea

    Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, June 08, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totali

  • GlobeNewswire

    Basilea shareholders approve all proposals of the board of directors at the annual general meeting

    Basel/Allschwil, Switzerland, April 26, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2022. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the financi

  • GlobeNewswire

    Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole

    Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, April 18, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, provided an updated timeline for its New Drug Application (NDA) submission for its antibiotic ceftobiprole to the US Food and Drug Administration (FDA). Basilea estimates that an additional three to six months of preparatory work will be req

  • GlobeNewswire

    Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan

    – Milestone related to the launch of Cresemba in Japan Basel/Allschwil, Switzerland, March 23, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced today that its license partner Asahi Kasei Pharma (“AKP”) has reported the achievement of a milestone related to the launch of Cresemba® (isavuconazole) in Japan, which triggered a CHF 5 million payment from AKP to Basi

  • GlobeNewswire

    Basilea reports strong financial results 2022 based on successful implementation of new strategy

    22% year-on-year increase of royalty income from antifungal Cresemba®Operating profit of CHF 18.5 million and net profit of CHF 12.1 millionStrengthened balance sheet through non-dilutive repayment of convertible bondsExpecting approximately 20% growth in Cresemba and Zevtera related revenue in 2023 and significant increase in net profitWell positioned for building an anti-infectives R&D portfolio to support sustainable long-term growth Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil,

  • GlobeNewswire

    Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer

    Basel/Allschwil, Switzerland, February 07, 2023Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region and China exceeded the threshold triggering a sales milestone payment of USD 1.25 million.Da

  • GlobeNewswire

    Basilea reports preliminary operating profit for 2022, significantly above guidance

    Successful implementation of strategic decision to focus on anti-infectives and stronger than expected revenue lead to profitability earlier than anticipated Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, January 24, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced today that on an unaudited preliminary basis it expects to have achieve

  • GlobeNewswire

    Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

    Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%Significant proceeds from oncology transactionsFollowing pre-NDA (New Drug Application) meeting held with FDA in Q4 2022 for ceftobiprole (Zevtera), NDA submission for three indications planned within two to three monthsBuilding a balanced R&D portfolio of antibacterial and antifungal drug candidates to support sustainable long-term growth in

  • GlobeNewswire

    Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea

    Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, January 09, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales of the antifungal Cresemba® (isavuconazole) achieved by its partner Astellas Pharma Inc. (“Astellas”) in the United States in 2022 exceeded the threshold triggering a milestone payment of CH

  • GlobeNewswire

    Basilea announces repayment of 2022 convertible bonds

    Basel/Allschwil, Switzerland, December 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has fully repaid its 2.75% convertible bonds (ISIN CH0305398148), which were due on December 23, 2022, with an outstanding nominal amount of CHF 113.8 million. As there was no conversion, no shares have been issued and the share capital remains unchanged.

  • GlobeNewswire

    Basilea announces regulatory approval of antifungal Cresemba® (isavuconazole) in Japan

    Japanese regulatory authority granted marketing authorization to Basilea’s license partner, Asahi Kasei PharmaIntravenous and oral use of Cresemba approved for the treatment of adult patients with aspergillosis, mucormycosis, and cryptococcosis Basel/Allschwil, Switzerland, December 23, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license pa

  • GlobeNewswire

    Basilea announces transition milestone for oncology asset BAL0891, triggering milestone payment of USD 4 million by SillaJen

    Basel/Allschwil, Switzerland, December 19, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the achievement of a transition milestone for the oncology asset BAL0891 to SillaJen, Inc., triggering a pre-defined milestone payment of USD 4 million to Basilea. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, stated: “The teams of Basilea and SillaJen h

  • GlobeNewswire

    Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics

    Sale of Basilea’s novel preclinical CLK kinase inhibitorsTotal payments of up to CHF 354 million Third oncology transaction as part of Basilea’s strategic refocusing on anti-infectives Basel/Allschwil, Switzerland, November 2, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Twentyeight-Seven The

  • GlobeNewswire

    ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)

    Late breaker presentation at IDWeek 2022First double-blind registrational phase 3 study in Staphylococcus aureus bacteremiaCeftobiprole non-inferior to daptomycin, meeting primary endpoint and demonstrating similar secondary efficacy outcomes Basel/Allschwil, Switzerland, October 24, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that data from the succ

  • GlobeNewswire

    Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022

    First presentation of ERADICATE phase 3 study dataStudy met its primary and secondary endpoints comparing ceftobiprole versus daptomycin with or without aztreonam Basel/Allschwil, Switzerland, October 13, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that an abstract on the successfully completed phase 3 ERADICATE study1, evaluating ceftobiprole in th

  • GlobeNewswire

    Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium

    Basel/Allschwil, Switzerland, September 21, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today the closing of the previously announced CHF 75 million senior secured loan agreement with funds managed by Athyrium Capital Management, LP ("Athyrium"). Adesh Kaul, Chief Financial Officer of Basilea, said: “We are pleased to announce the closing of this loan agr

  • GlobeNewswire

    Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance

    Upfront and near-term milestone payments of USD 14 million Additional milestone payments of approximately USD 320 million and tiered royalties on net salesSecond oncology transaction as part of strategic refocusing on anti-infectivesFull-year 2022 revenue guidance increased, resulting in improved expected operating result and operating cash flow Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, September 20, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage b

  • GlobeNewswire

    Basilea announces sale of preclinical oncology program to Nodus Oncology

    Sale of Basilea’s novel PARG inhibitor discovery programUpfront and milestone payments of up to CHF 242 million and approximately 5% participation in net salesImportant step in implementing Basilea’s strategic refocus on anti-infectives Basel/Allschwil, Switzerland, September 08, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into

  • GlobeNewswire

    Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December 2022

    Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, September 07, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that is has entered into a senior secured loan agreement with funds managed by Athyrium Capital Management, LP ("Athyrium"). The CHF 75 million senior secured loan will be used by Basilea for the repayment of its convert

  • GlobeNewswire

    Basilea reports strong financial half-year results and progress in the implementation of new anti-infectives strategy

    CHF 29 million royalty income (+22.5% year-on-year) reflecting continued commercial success of CresembaContinued improvement of operating cash flow CHF 142 million cash, restricted cash and investments at half-year 2022Full-year 2022 guidance confirmed as well as expected sustainable profitability from 2023 Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, August 16, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today i

  • GlobeNewswire

    Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil

    Basel/Allschwil, Switzerland, July 12, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its distribution partner for Latin America, Knight Therapeutics Inc. (“Knight”, TSX: GUD), has received a marketing authorization from the Agência Nacional de Vigilância Sanitária (Anvisa) in Brazil for the broad-spectrum, anti-MRSA (methicillin-resistant Staphylococcus aureus) antibiotic Zevtera® (ceftobiprole). Zevtera is indicated for the treatm

  • GlobeNewswire

    Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)

    Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022 Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, June 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today positive topline results for the phase 3 ERADICATE study, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcu

  • GlobeNewswire

    Basilea reports progress on the implementation of its strategy to focus on anti-infectives

    ERADICATE phase 3 study exploring ceftobiprole for the treatment of patients with Staphylococcus aureus bacteremia (SAB) expected to report results shortlySeparate transactions for TTK/PLK1 inhibitor (BAL0891) and preclinical oncology projects expected to be concluded in H2 2022 No expansion of ongoing lisavanbulin clinical studies; exploring partnering opportunitiesDerazantinib rights to be transferred back to Merck & Co. by the end of 2022No material expenses related to oncology activities bey

  • GlobeNewswire

    Basilea announces approval for additional formulation of antifungal Cresemba® (isavuconazole) in China

    Chinese National Medical Products Administration (NMPA) granted Drug Approval License to Basilea’s license partner, Pfizer Inc.Intravenous use of Cresemba approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis following previous approval of oral dosage form Basel/Allschwil, Switzerland, June 24, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its license partner, Pfizer Inc. (NYSE: PFE, “P

  • GlobeNewswire

    Cresemba® sales in Asia Pacific region trigger sales milestone payment to Basilea from Pfizer

    Basel/Allschwil, Switzerland, June 17, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that the sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. (NYSE: PFE, “Pfizer”) in the Asia Pacific region, exceeded the threshold triggering the first sales milestone payment for this region of USD 1.25 million. David Veitch, Basilea’s Chief Executive Officer, stated: “We are very pleased with the commercial progress